產(chǎn)品屬性：
產(chǎn)品名稱 | Trastuzumab deruxtecan |
規(guī)格 | 1mg (10 mg/mL * 100 μL in Aqueous solution) |
貨號(hào) | EY-01Y15214 |
Cas No.: 1826843-81-5
別名: N/A
化學(xué)名: N/A
分子式: N/A
分子量: N/A
溶解度: N/A
儲(chǔ)存條件: Solution, -20°C, 2 years
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC50 of 109.7 pM[2].Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells[2].Cell Viability Assay[2]Cell Line:KPL‐4 and MDA‐MB‐468 cellsTrastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition[2].Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3].
特別提醒公司產(chǎn)品僅供科研使用
